ULTACAN FORTE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ultacan Forte, and when can generic versions of Ultacan Forte launch?
Ultacan Forte is a drug marketed by Hansamed Inc and is included in one NDA.
The generic ingredient in ULTACAN FORTE is articaine hydrochloride; epinephrine bitartrate. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the articaine hydrochloride; epinephrine bitartrate profile page.
Summary for ULTACAN FORTE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ULTACAN FORTE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ULTACAN FORTE
US Patents and Regulatory Information for ULTACAN FORTE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hansamed Inc | ULTACAN FORTE | articaine hydrochloride; epinephrine bitartrate | INJECTABLE;INJECTION | 201750-001 | Jul 11, 2017 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |